Cite
HARVARD Citation
Sammons, S. et al. (2022). Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert review of anticancer therapy. 22 (8), pp. 805-814. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sammons, S. et al. (2022). Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert review of anticancer therapy. 22 (8), pp. 805-814. [Online].